Post Profile

FDA staff flag concerns about Allergan's urinary drug

(Reuters) - The proposed dosing for a drug being developed by Allergan Plc to treat frequent urination at night has not been adequately studied in trials, a preliminary review by the U.S. Food and Drug Administration staff concluded...
read more

See more about: Drug Administration

Related Posts

FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair

Health : Medical News Today

The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a...

Urine Analyzer IPhone App Concerns FDA

Health : Medical News Today

The U.S. Food and Drug Administration has sent a letter to the developer of a mobile app called "uChek Urine analyzer" stating that the company requires regulatory approval of its mobile app which is able to analyze photos of urine ...

FDA Accepts SNDA For Alternative Dosing Regimen For Dacogen(R) (decitabine For Injection) To Treat Patients With Myelodysplastic Syndromes (MDS)

Health : Medical News Today

Eisai Corporation of North America announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (...

FDA staff flags concerns about Pfizer's quit-smoking drug study

Health : Reuters: Health

(Reuters) - U.S. Food and Drug Administration scientists have expressed concerns about a post-marketing study of Pfizer Inc's drug Chantix, which is aimed at helping smokers quit, according to documents posted on the regulator's web...

FDA panel backs Allergan's drug for frequent nightly urination

Health : Reuters: Health

(Reuters) - The benefits associated with Allergan Plc's experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday...


Copyright © 2016 Regator, LLC